Literature DB >> 21801975

The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.

Doreen M Rabi1, Stella S Daskalopoulou, Raj S Padwal, Nadia A Khan, Steven A Grover, Daniel G Hackam, Martin G Myers, Donald W McKay, Robert R Quinn, Brenda R Hemmelgarn, Lyne Cloutier, Peter Bolli, Michael D Hill, Thomas Wilson, Brian Penner, Ellen Burgess, Maxime Lamarre-Cliché, Donna McLean, Ernesto L Schiffrin, George Honos, Karen Mann, Guy Tremblay, Alain Milot, Arun Chockalingam, Simon W Rabkin, Martin Dawes, Rhian M Touyz, Kevin D Burns, Marcel Ruzicka, Norman R C Campbell, Michel Vallée, G V Ramesh Prasad, Marcel Lebel, Tavis S Campbell, M Patrice Lindsay, Robert J Herman, Pierre Larochelle, Ross D Feldman, J Malcolm O Arnold, Gordon W Moe, Jonathan G Howlett, Luc Trudeau, Simon L Bacon, Robert J Petrella, Richard Lewanczuk, James A Stone, Denis Drouin, Jean-Martin Boulanger, Mukul Sharma, Pavel Hamet, George Fodor, George K Dresser, S George Carruthers, George Pylypchuk, Richard E Gilbert, Lawrence A Leiter, Charlotte Jones, Richard I Ogilvie, Vincent Woo, Philip A McFarlane, Robert A Hegele, Luc Poirier, Sheldon W Tobe.   

Abstract

We updated the evidence-based recommendations for the diagnosis, assessment, prevention, and treatment of hypertension in adults for 2011. The major guideline changes this year are: (1) a recommendation was made for using comparative risk analogies when communicating a patient's cardiovascular risk; (2) diagnostic testing issues for renal artery stenosis were discussed; (3) recommendations were added for the management of hypertension during the acute phase of stroke; (4) people with hypertension and diabetes are now considered high risk for cardiovascular events if they have elevated urinary albumin excretion, overt kidney disease, cardiovascular disease, or the presence of other cardiovascular risk factors; (5) the combination of an angiotensin-converting enzyme (ACE) inhibitor and a dihydropyridine calcium channel blocker (CCB) is preferred over the combination of an ACE inhibitor and a thiazide diuretic in persons with diabetes and hypertension; and (6) a recommendation was made to coordinate with pharmacists to improve antihypertensive medication adherence. We also discussed the recent analyses that examined the association between angiotensin II receptor blockers (ARBs) and cancer.
Copyright © 2011 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21801975     DOI: 10.1016/j.cjca.2011.03.015

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  30 in total

1.  Delaying blood pressure control in type 2 diabetes: illustrating principles in the practice of medicine.

Authors:  Raj S Padwal; Scott W Klarenbach
Journal:  J Gen Intern Med       Date:  2012-06       Impact factor: 5.128

Review 2.  Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes.

Authors:  Doreen M Rabi; Raj Padwal; Sheldon W Tobe; Richard E Gilbert; Lawrence A Leiter; Robert R Quinn; Nadia Khan
Journal:  CMAJ       Date:  2013-06-03       Impact factor: 8.262

3.  Best thiazide diuretic for hypertension.

Authors:  G Michael Allan; Noah Ivers; Raj S Padwal
Journal:  Can Fam Physician       Date:  2012-06       Impact factor: 3.275

Review 4.  A practical guide to monitoring for adverse drug reactions during antihypertensive drug therapy.

Authors:  Sarah E McDowell; Sarah K Thomas; Jamie J Coleman; Jeffrey K Aronson; Robin E Ferner
Journal:  J R Soc Med       Date:  2013-03       Impact factor: 5.344

5.  Imputing observed blood pressure for antihypertensive treatment: impact on population and genetic analyses.

Authors:  Brinda K Rana; Anish Dhamija; Matthew S Panizzon; Kelly M Spoon; Terrie Vasilopoulos; Carol E Franz; Michael D Grant; Kristen C Jacobson; Kathleen Kim; Michael J Lyons; Jeanne M McCaffery; Phyllis K Stein; Hong Xian; Daniel T O'Connor; William S Kremen
Journal:  Am J Hypertens       Date:  2014-02-14       Impact factor: 2.689

6.  Filling in the pieces of the sleep apnea-hypertension puzzle.

Authors:  Vishesh K Kapur; Edward M Weaver
Journal:  JAMA       Date:  2012-05-23       Impact factor: 56.272

Review 7.  Comparative effectiveness research in the "real" world: lessons learned in a study of treatment-resistant hypertension.

Authors:  Marilyn A Laken; Rosalind Dawson; Otis Engelman; Oscar Lovelace; Charles Way; Brent M Egan
Journal:  J Am Soc Hypertens       Date:  2013 Jan-Feb

8.  The role of compliance with PAP use on blood pressure in patients with obstructive sleep apnea: is longer use a key-factor?

Authors:  I Bouloukaki; C Mermigkis; N Tzanakis; K Giannadaki; E Mauroudi; V Moniaki; E M Kallergis; S E Schiza
Journal:  J Hum Hypertens       Date:  2016-07-28       Impact factor: 3.012

9.  Pay-for-performance remuneration for pharmacist prescribers' management of hypertension: A substudy of the RxACTION trial.

Authors:  Sherilyn K D Houle; Theresa L Charrois; Finlay A McAlister; Michael R Kolber; Meagen M Rosenthal; Richard Lewanczuk; Norman R C Campbell; Ross T Tsuyuki
Journal:  Can Pharm J (Ott)       Date:  2016-10-03

10.  Antihypertensive use before and after initiation of fixed-dose combination products in Australia: a retrospective study.

Authors:  Svetla Gadzhanova; Jenni Ilomäki; Elizabeth E Roughead
Journal:  Int J Clin Pharm       Date:  2013-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.